LBF20207PG31: Difference between revisions
No edit summary |
No edit summary |
||
(3 intermediate revisions by the same user not shown) | |||
Line 6: | Line 6: | ||
|LipidBank=XPR1719 | |LipidBank=XPR1719 | ||
|LipidMaps=LMFA03010036 | |LipidMaps=LMFA03010036 | ||
|SysName=9alpha,11beta,15S- | |SysName=(9alpha,11beta,15S) -Trihydroxy-prosta- (cis-5,trans-13) -dien-1-oic acid | ||
|Common Name=&&11beta- Prostaglandin | |Common Name=&&11beta- Prostaglandin F_2 alpha&&(9alpha,11beta,15S) -Trihydroxy-prosta- (5Z,13E) -dien-1-oic acid | ||
|Source=11 beta -PGF2 alpha is the primary plasma metabolite of PGD2 in vivo.[[Reference:Liston_TE:Roberts_LJ:2nd:,Proc. Natl. Acad. Sci. U. S. A.,1985,82,6030|{{RelationTable/GetFirstAuthor|Reference:Liston_TE:Roberts_LJ:2nd:,Proc. Natl. Acad. Sci. U. S. A.,1985,82,6030}}]] | |Source=11 beta -PGF2 alpha is the primary plasma metabolite of PGD2 in vivo.[[Reference:Liston_TE:Roberts_LJ:2nd:,Proc. Natl. Acad. Sci. U. S. A.,1985,82,6030|{{RelationTable/GetFirstAuthor|Reference:Liston_TE:Roberts_LJ:2nd:,Proc. Natl. Acad. Sci. U. S. A.,1985,82,6030}}]] | ||
|Chemical Synthesis= | |Chemical Synthesis= |
Latest revision as of 08:32, 21 October 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR1719 |
LipidMaps | LMFA03010036 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20207PG31 |
11β- Prostaglandin F2α | |
---|---|
Structural Information | |
(9α,11β,15S) -Trihydroxy-prosta- (cis-5,trans-13) -dien-1-oic acid | |
| |
Formula | C20H34O5 |
Exact Mass | 354.240624198 |
Average Mass | 354.48096000000004 |
SMILES | C(CC[C@@H](O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)[C@H](C[C@@H]1O)O)CC |
Physicochemical Information | |
11 beta -PGF2 alpha is the primary plasma metabolite of PGD2 in vivo. Liston_TE et al. | |
Spectral Information | |
Mass Spectra | |
UV Spectra | |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
|